Trabectedin clinical cases: use according to indication in diverse clinical scenarios

Giovanni Grignani1, Javier Martín-Broto2, Markus Schuler3

  • 11Medical Oncology Unit, Candiolo Cancer Institute - FPO, IRCCS, Italy.

Abstract

Insights

Trabectedin offers prolonged tumor control and maintains quality of life in advanced soft tissue sarcoma patients. This drug demonstrates efficacy across various subtypes, including uterine leiomyosarcoma and synovial sarcoma.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Trabectedin is indicated for advanced soft tissue sarcoma (STS) post-anthracycline/ifosfamide failure or as first-line for ineligible patients.
  • Key features include prolonged tumor control, efficacy in translocation-related sarcomas, response maintenance, rechallenge option, and minimal cumulative toxicity.

Observation:

  • Case studies reviewed trabectedin use in diverse clinical settings within its approved indications.
  • Specific cases involved second-line treatment for uterine leiomyosarcoma, recurrent synovial sarcoma, and neoadjuvant therapy for undifferentiated pleomorphic sarcoma.

Findings:

  • Trabectedin provided prolonged tumor control and good quality of life in uterine leiomyosarcoma.
  • Recurrent synovial sarcoma achieved best objective response and longest disease control (37 months) with trabectedin.
  • Neoadjuvant trabectedin in undifferentiated pleomorphic sarcoma resulted in 85% tumor necrosis.

Implications:

  • These cases highlight trabectedin's broad utility in advanced STS.
  • Optimizing trabectedin's unique characteristics can maximize clinical benefit in soft tissue sarcoma treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
916
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
76